Monitoring human immunodeficiency virus type 1-infected patients by ratio of antibodies to gp41 and p24.
Antibody responses of 85 patients to human immunodeficiency virus type 1 antigens were quantitated by densitometric analysis of Western blot (immunoblot) assays. All patients had been classified into the following three clinical categories: asymptomatic (ASY), acquired immunodeficiency syndrome (AIDS)-related complex (ARC), or AIDS. Fifty of the patients were monitored for 6 to 29 months. The gp41/p24 antibody ratio was examined in three studies. In the first study, initial specimens from each patient were analyzed. The mean gp41/p24 antibody ratios were 1.5 (ASY), 3.2 (ARC), and 5.4 (AIDS). Of ASY patients, 79% had antibody ratios of less than 2.0. In contrast, 72% of patients with AIDS had ratios of greater than or equal to 2.0. In the second study, serially obtained specimens from ASY, ARC, and AIDS patients were analyzed. These patients were further grouped according to progression of their clinical condition. Of ASY patients whose clinical condition progressed to ARC, 80% consistently had ratios of greater than or equal to 2.0. Of ARC patients whose clinical condition progressed to AIDS, 71% consistently had ratios of greater than or equal to 2.0. Of AIDS patients who died during the study, 100% consistently had ratios of greater than or equal to 2.0. No patients were treated with azidothymidine during the first two studies. In the third study, AIDS patients were monitored before and during treatment with azidothymidine. During treatment, ratios stabilized or improved transiently in five of seven patients. In these three studies, a gp41/p24 antibody ratio of less than 2.0 correlated with a benign clinical state and a ratio of greater than or equal to 2.0 correlated with AIDS or progression to AIDS.
Schmidt
G
G
Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany 12201.
Amiraian
K
K
Frey
H
H
Wethers
J
J
Stevens
R W
RW
Berns
D S
DS
D000386:AIDS-Related Complex / Q000188:drug therapy / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000276:immunology*; D015153:Blotting, Western; D003720:Densitometry; D015483:HIV Antibodies / Q000032:analysis*; D015488:HIV Antigens / Q000276:immunology*; D016655:HIV Core Protein p24; D015700:HIV Envelope Protein gp41; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D011379:Prognosis; D012191:Retroviridae Proteins / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology*; D015215:Zidovudine / Q000627:therapeutic use
D015483:HIV Antibodies; D015488:HIV Antigens; D016655:HIV Core Protein p24; D015700:HIV Envelope Protein gp41; D012191:Retroviridae Proteins; D014759:Viral Envelope Proteins; D015215:Zidovudine